Study of Key Electro-acupuncture Technique on Migraine

Migraine Clinical Trial

Official title:

Study of Key Electro-acupuncture Technique on Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02580968
• Other study ID #: 643857003534
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Est. completion date: December 2017

Study information

• Verified date: February 2020
• Source: Shanghai University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A random controlled trail to evaluate the efficacy of migraine standard electroacupuncture formula, and to analysis the regulation of the intensity-effects and to observe the peripheral NO, CGRP and NF-кB expression level of migraine patients after electroacupuncture treatment.

Description:

acupuncture group(group A): treated by acupuncture for 20 days, 1 time per day control group(group B): treated by FlunarizineHydrochloride for 20 days, 1 table per day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• met the diagnostic criteria for migraine; suffering from migraine attacks; migraine attacks for more than 5 days per month, and lasts for 3 months; voluntarily join this study with informed consents.

Exclusion Criteria:

• other systemic, neurological and psychiatric disorders; headache caused by other diseases; not treatment compliance during the study.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• electro-acupuncture
electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.

Drug:
• flunarizine hydrochloride
flunarizine hydrochloride ,10mg/day,for 20 days?

Locations

Country	Name	City	State
China	Longhua Hospital,Shanghai University of Traditional Chinese Medicine	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Migraine Disability Assessment Questionnaire (MIDAS)	a scientifically reliable and valid measure of migraine disability that can improve communication between patients and physicians, assess migraine severity and act as an outcome measure to monitor treatment efficacy	20 days
Secondary	The medical outcomes study 36-item short-form health survey(SF-36)	A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study	20 days
Secondary	peripheral Nitrogen Monoxide(NO) protein expression	marker	20 days
Secondary	peripheral Calcitonin gene related peptide(CGRP) protein expression	marker	20 days
Secondary	peripheral Nuclear factor-kappa B(NF-?B) protein expression	marker	20 days
Secondary	Visual Analogue Scale (VAS) to assess pain	Visual Analogue Scale (VAS) were applied to measure pain in patients	20 days